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Objective: To report a good clinical outcome in a patient with bilateral choroidal 
neovascularization (CNV) associated with optic nerve head drusen (ONHD) treated with 
intravitreal ranibizumab injection.
Methods: A 12-year-old girl was referred for loss of right eye vision detected in a routine 
check-up. Best-corrected visual acuity (BCVA) was hand movements in the right eye and 0.9 in 
the left eye. Funduscopy revealed the presence of superficial and buried bilateral ONHD, which 
was confirmed by ultrasonography and computed tomography, and the study was completed with 
perimetry. The presence of bilateral CNV , active in the right eye, was observed and subsequently 
confirmed using fluorescein angiography and optical coherence tomography.
Results: Treatment with two consecutive injections of intravitreal ranibizumab resulted in 
inactivation of the neovascular membrane with subretinal fluid reabsorption and improved right 
eye BCVA. After 12 months’ follow-up, this was 20/60 and stable.
Conclusion: Although there are no published studies of safety in children, antiangiogenic 
therapy for CNV secondary to ONHD may be useful and safe. A search of the literature   produced 
only one previously reported case of ONHD-associated CNV treated with antivascular endothe-
lial growth factor alone.
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Introduction
Optic nerve head drusen (ONHD) are found in 3.4–24 individuals per 1000 population, 
bilaterally in 75% of cases. Most are detected in a routine eye examination without 
the patient reporting visual loss or other symptoms.1 Regarding location, ONHD 
may be superficial or buried, in which case differential diagnosis with other causes 
of pseudopapilledema is required. In children, superficial drusen are rare; it is more 
common to see congestive papillae without excavation due to the accumulation of 
extracellular material in deeper layers.2 With age, drusen increase in size and become 
more visible, so in adults we observe filled papillae with kidney-shaped edges and 
irregular glistening white points.
Most patients with ONHD are asymptomatic and diagnosed incidentally in routine 
funduscopy. Those with symptoms often report insidious visual loss due to visual field 
alterations, and sudden visual loss is rare. ONHD progressively increase in size with 
age, becoming more visible due to the accumulation of calcium, which correlates with 
progression of visual field defects. The natural history of ONHD is variable, and in 
some cases spontaneous involution has been described.3 Although there is currently no 
effective treatment, correct diagnosis is essential to differentiate it from papilledema, Clinical Ophthalmology 2012:6 submit your manuscript | www.dovepress.com
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in order to avoid unnecessary neurological examinations and 
especially to rule out neurological pathology compatible with 
the appearance of pseudopapilledema.
The diagnosis of ONHD is made by funduscopy in most 
cases. However, additional examinations may be useful to 
confirm the diagnosis or, in doubtful cases, to detect possible 
complications.
B-scan ultrasound is particularly useful to detect deep cal-
cium deposits, which appear as highly reflective oval lesions 
with posterior acoustic shadowing when using medium and 
low frequencies.4 In fact, ultrasound is the tool of choice 
for the detection of ONHD, although the experience of the 
sonographer is essential to detect small-sized drusen.5,6
The calcium content of ONHD is what makes them 
appear as bright spots in computed tomography (CT), which 
is considered a superior method for detecting deep drusen 
compared with ophthalmoscopy. It also offers the   advantage 
of allowing possible intracranial mass to be ruled out.7 
  However, the amplitude of CT cuts used at the optic nerve 
head means that small drusen are sometimes not reflected, 
making it less sensitive than ultrasound for detection. This, 
added to high cost and difficulty of use, limits the usefulness 
of CT for initial diagnosis of ONHD.
ONHD are autofluorescent, so they emit a glow when 
viewed through filters prior to fluorescein injection. This 
phenomenon is due to the calcified refractile material that 
composes the drusen. Fundus autofluorescence imaging is 
more sensitive than ophthalmoscopy for the detection of 
drusen but less so than ultrasound.8
In fluorescein angiography (FA) we observe hyperfluo-
rescence of the optic disk. This technique allows us to dif-
ferentiate ONHD from other entities such as papilledema 
or neovascularization, where the initial hyperfluorescence 
increases during the angiogram due to contrast extravasation. 
Although FA is technically unnecessary for the diagnosis of 
ONHD, it is useful for detecting and monitoring some of the 
complications.
Optical coherence tomography (OCT) provides early evi-
dence of retinal nerve fiber layer thinning, which is associated 
with an increase in the quantity and/or size of drusen.8 Like 
FA, it is a very useful technique in the management of some 
vascular complications associated with ONHD.
Despite the generally benign nature of the picture, there 
may be vascular complications that compromise visual 
prognosis in these patients, including choroidal neovascular-
ization (CNV), ischemic optic neuritis, central retinal artery 
occlusion, central retinal vein occlusion, and retinal or optic 
nerve hemorrhage. Among the possible mechanisms involved 
in these complications is the compressive effect of drusen on 
surrounding blood vessels, causing mechanical damage of 
vascular integrity, vascular congestion, or ischemia.
CNV associated with ONHD has been described but 
remains a very rare complication. In the few existing pub-
lished cases, CNV was treated with laser photocoagulation, 
photodynamic therapy, or macular surgery. To our 
  knowledge, the literature contains only one case where CNV 
secondary to ONHD was treated with antivascular endothelial 
growth factor (anti-VegF) alone,9 and another case with 
intravitreal ranibizumab (IVR) injection combined with laser 
  photocoagulation.10 This combined strategy yielded good 
results in both cases but does not allow any conclusions on the 
therapeutic utility of IVR alone. We report the second case 
of treatment with IVR alone for CNV secondary to ONHD, 
with no adverse effects and good response.
Case report
A 12-year-old girl was referred to the ophthalmology depart-
ment at Terrassa Hospital, Barcelona, Spain, by a private 
optician who, in a routine eye examination, found right eye 
best-corrected visual acuity (BCVA) of counting fingers at 
20 cm and 20/20 in the left eye. The patient reported no loss 
of vision or other associated symptoms and had no personal 
or family history of interest. Intraocular pressure and anterior 
segment examination were normal. Funduscopy revealed 
the presence of bilateral superficial ONHD, marked venous 
congestion and arterial stenosis, the presence of fibrous CNV 
in the papillomacular bundle in both eyes, and serous 
  detachment of the retina in the right eye reaching the macular 
area (Figures 1 and 2). B-scan ultrasound (Figure 3) and CT 
Figure  1  Optic  nerve  head  drusen  associated  with  an   active  choroidal 
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(Figure 4) confirmed the suspected diagnosis of bilateral 
ONHD, and FA revealed the presence of active extrafoveal 
CNV in the papillomacular bundle of the right eye and 
bilateral pigment epithelial atrophy in the juxtapapillary area 
temporal to the optic nerve (Figures 5 and 6). OCT revealed 
the presence of a juxtafoveal CNV in both eyes with associ-
ated subretinal fluid in the right eye (Figure 7) and a foveal 
thickness of 318 µm. The visual field was not evaluated in 
the right eye due to lack of fixation, and deep, extensive 
scotomas were observed in the left eye (Figure 8).
With a diagnosis of choroidal neovascular membrane 
(NVM) secondary to optic nerve drusen, we obtained 
informed consent to administer treatment with IVR 
injection, given at a dose of 0.5 mg (0.05 mL) with a 
30-gauge needle 4 mm from the limbus, under sedation, and 
after application of topical anesthesia with 2% lidocaine, 
under strict asepsis. The patient was treated with topical 
quinolone three times a day for a week after intravitreal 
injection. The next day, and 1 week later, intraocular pres-
sure (IOP) was measured and slit-lamp examination and 
funduscopy were performed. One month after the injection, 
IOP was normal, visual acuity was two early Treatment 
Diabetic Retinopathy Study letters at 4 meters, fundus 
examination revealed no changes from previous visits, 
and OCT showed persistence of minimal subretinal fluid, 
so a second injection of IVR was administered. After the 
Figure 2 Fibrous choroidal neovascularization in the papillomacular bundle without 
activity on the left eye.
Figure 3 Ultrasound of (A) right eye and (B) left eye.
Figure 4 Computed tomography.
Figure 5 Initial fluorescein angiography.Clinical Ophthalmology 2012:6 submit your manuscript | www.dovepress.com
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second injection the same pattern of visits was followed. 
At 4 weeks after the second injection, visual acuity was 
20/60. Fundus examination showed the NVM without fluid, 
confirmed by OCT, which also showed a foveal thickness 
of 295 µm. From then on, successive visits were made 
every 6 weeks, with BCVA, IOP, anterior and posterior 
segment examination, and OCT performed and found 
to remain stable at every visit. At the end of follow-up, 
12 months after the first visit, OCT showed no subretinal 
fluid and right eye BCVA remained stable at 20/60. The 
left eye showed no signs of activity at any time. The patient 
receives regular monitoring for the early detection of 
  possible complications.
Discussion
The prevalence of ONHD is very low and their association 
with CNV is extremely rare, with no established treat-
ment regimen. The natural evolution of CNV associated 
with ONHD is highly variable, and even spontaneous 
involution has been described. The macula may be 
affected early in the progression of the lesion, either by 
direct extension of the NVM or by associated serous or 
hemorrhagic retinal detachment, severely compromis-
ing visual prognosis.
Over the years, many treatment models have been 
  proposed. Laser photocoagulation was for many years 
the most widely used treatment for this type of NVM,11 
although the residual scotoma it produced meant that it was 
contraindicated in NVM with subfoveal location. Macu-
lar surgery also showed good results, although the added 
surgical risk in these cases required consideration.12
Some investigators have advocated the use of photo-
dynamic therapy with verteporfin as safe and effective 
for the treatment of CNV associated with symptomatic 
ONHD.13–15
Antiangiogenic therapy is currently the treatment of 
choice for the treatment of CNV secondary to age-related 
macular degeneration (AMD). It is also indicated for the 
treatment of CNV associated with entities such as high 
myopia,16,17 macular edema associated with vascular 
  occlusion18 or diabetes mellitus,19 and premature retinopathy 
of prematurity.20
Conclusion
With the introduction of anti-VegF therapy into daily 
practice in recent years, the prognosis of retinal disease has 
changed dramatically, to the point where this therapy has 
succeeded in changing the course of the disease in some 
cases. This is most evident in AMD, but anti-VegF for other 
entities such as vascular occlusion or diabetic retinopathy has 
also been extensively studied, with good results.
CNV secondary to ONHD is highly unusual, and widely 
varying treatment options have been used over the years. 
Although there are no recommendations in this regard, the 
results obtained in our patient indicate that antiangiogenic 
therapy can be useful and safe for the treatment of CNV 
secondary to optic disk drusen. Larger series are needed to 
confirm this. The favorable response reported here suggests a 
further example of the utility of IVR to be added to its known 
Figure 6 Fluorescein angiography.
Figure 7 Optical coherence tomography of the right eye.Clinical Ophthalmology 2012:6 submit your manuscript | www.dovepress.com
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beneficial effects on NVM associated with other entities such 
as AMD and high myopia.
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